Evaxion Biotech A/S (EVAX) Stock
Evaxion Biotech A/S Chart
Company Profile
Price: $2.49
Market Cap: $780.19K
Exchange: NASDAQ
CEO: Mr. Christian Kanstrup M.Sc.
Sector: Healthcare
Industry: Biotechnology
Employees: 49
Headquarters: Horsholm, None
Website: Evaxion Biotech A/S
Business Summary
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Evaxion Biotech A/S News
Evaxion announces closing of $10.8 million public offering
COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of a public offering of an aggregate of 3,997,361 of its American Depositary Shares (“ADSs”) and warrants to purchase up to 50% of the ADSs offered at a combined public offering price of $2.71 per ADS with one accompanying warrant for each two ADSs.
Evaxion announces pricing of $10.8 million public offering
COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the pricing of a public offering of an aggregate of 3,997,361 of its American Depositary Shares (“ADSs”) and warrants to purchase up to 50% of the ADSs offered at a combined public offering price of $2.71 per ADS with one accompanying warrant for each two ADSs.
Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement
COPENHAGEN, Denmark, January 28, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has received notice from the Nasdaq Stock Market LLC (“Nasdaq”) that it has been granted a 180-day extension to comply with Nasdaq's minimum stockholder's equity requirement. Meanwhile, Evaxion has already restored its equity above the Nasdaq minimum requirement.
Evaxion announces completion of ADS ratio change
COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that the Company's previously disclosed ratio change of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), has been made effective.
Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change
COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it is amending the effective date for its plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS ratio”), from the current one (1) ADS representing ten (10) ordinary share to a new ADS ratio of one (1) ADS representing fifty (50) ordinary shares (the “ADS ratio change”).
Evaxion announces plan to implement ADS ratio change
COPENHAGEN, Denmark, December 30, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS ratio”), from the current one (1) ADS representing ten (10) ordinary share to a new ADS ratio of one (1) ADS representing fifty (50) ordinary shares (the “ADS ratio change”). The ADS ratio change is expected to become effective on or about January 13, 2025, U.S. Eastern Time (the “effective date”).
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new positive preclinical data from its ongoing cytomegalovirus (CMV) vaccine program named EVX-V1. The data will be presented today at the 9th International Conference on Vaccines Research & Development, taking place in Boston, USA.
Evaxion announces business update and third quarter 2024 financial results
COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces third quarter 2024 financial results.
Evaxion to announce business update and third quarter 2024 financial results on October 31
COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM.
Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials
COPENHAGEN, Denmark, October 9, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has now evidence from three different clinical trials validating the vaccine target predictions of its AI platform.
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
COPENHAGEN, Denmark, October 3, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, continues to gather clinical evidence for the steady improvement of its AI-Immunology™ platform.
Evaxion significantly expands vaccine development collaboration with MSD
COPENHAGEN, Denmark, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it has entered into an option and license agreement with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) for two preclinical vaccine candidates. The agreement expands the companies' current collaboration and carries significant value for Evaxion.
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
COPENHAGEN, Denmark, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, launches an enhanced version of its clinically validated AI-Immunology™ platform with an update of its EDEN™ AI prediction model. Among other improvements, the model can now predict toxin antigens, allowing for the development of improved bacterial vaccines.
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
COPENHAGEN, Denmark, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new pre-clinical data demonstrating the ability of its novel EVX-B2 mRNA Gonorrhea vaccine candidate in eliminating gonorrhea bacteria by triggering a targeted immune response.
Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript
Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rono - Chief Scientific Officer Jesper Nissen - Chief Operating Officer and Chief Financial Officer Mads Kronborg - Vice President, Investor Relations & Communication Conference Call Participants Li Chen - H.C. Wainwright Thomas Flaten - Lake Street Capital Markets Chong Liu - Ladenburg Operator Good day and thank you for standing by.
Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results on Wednesday, August 14, 2024, before opening of the Nasdaq-CM.
Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September
COPENHAGEN, Denmark, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is proud to announce the presentation of one-year clinical efficacy Phase 2 data for its lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2024, taking place in Barcelona, Spain, from September 13-17, 2024. The EVX-01 vaccine is a personalized therapy currently being assessed in patient with advanced melanoma (skin cancer).
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
COPENHAGEN, Denmark, July 16, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today showcases improved performance of its key building block, EvaxMHC, within its AI-Immunology™ platform, at the 32nd Intelligent Systems for Molecular Biology (ISMB) conference taking place in Montreal, Canada, from July 12-16, 2024.
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders.
Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
COPENHAGEN, Denmark, June 26, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, receives positive feedback on its recent patent application for a new type of personalized vaccine targets, underscoring its novelty and inventiveness.
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
COPENHAGEN, Denmark, June 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces publication of data from its Phase 1 dose escalation study of its lead personalized cancer vaccine candidate, EVX-01, for metastatic melanoma. The study results, published in the Journal for ImmunoTherapy of Cancer , demonstrated that eight out of 12 patients (67%) experienced objective clinical responses (ORR) with six partial and two complete responses. Further, EVX-01 immunization did not induce vaccine-related serious adverse events in patients co-administered with anti-PD1 therapy.
Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now
Evaxion Biotecch (EVAX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
COPENHAGEN, Denmark, June 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, reported data from its ongoing Phase 2 study at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. The data demonstrated vaccine-induced immune response in metastatic melanoma patients treated with the Company's AI-Immunology™ designed personalized cancer vaccine, EVX-01, in combination with an anti-PD1 inhibitor. The EVX-01 vaccine targets neoantigens - antigenic sequences derived from cancer mutations - that are displayed on the surface of the cancer cells, allowing the immune system to recognize, attack and eliminate the malignant cells.
Evaxion Announces Business Update and First Quarter 2024 Financial Results
COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2024 financial results.
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
COPENHAGEN, Denmark, May 23, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announces its participation in the American Society of Clinical Oncology (ASCO) Annual Meeting, where it will present positive immune data form its ongoing EVX-01 Phase 2 study. The study assesses the personalized cancer vaccine EVX-01 in combination with anti-PD1 therapy in patients with advanced melanoma. The conference will take place in Chicago, IL, from May 31 – June 4, 2024.
Evaxion Receives Nasdaq Notification
COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on May 7, 2024, it received a letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department notifying the Company that it is not currently in compliance with the minimum stockholders' equity requirement.
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
COPENHAGEN, Denmark, April 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA® (NCT05309421).
Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript
Evaxion Biotech A/S (EVAX) Q4 2023 Results Conference Call April 2, 2024 9:00 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rono - Chief Scientific Officer Jesper Nissen - Chief Operating Officer and Chief Financial Officer Conference Call Participants Ahu Demir - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Thomas Flaten - Lake Street Capital Markets Richard Ramanius - Redeye Christian Kanstrup Hello, everyone, and a very warm welcome to this Evaxion Business Update Conference call on the back of our Full Year 2023 Results.
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
COPENHAGEN, Denmark, April 02, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is pleased to announce the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from Evaxion's preclinical EVX-B1 vaccine candidate against Staphylococcus aureus (S. aureus). In the animal studies, the EVX-B1 antigens significantly reduced disease burden. Currently, the two companies are engaged in discussions regarding the path forward.
Evaxion Biotech A/S Earnings
This section highlights Evaxion Biotech A/S's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q2 | 2024 | 2024-08-14 | $0.10 | $-0.60 |
| Read Transcript | Q4 | 2023 | 2024-04-02 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-08-22 | N/A | N/A |
Financial Statements
Access annual & quarterly financial statements for Evaxion Biotech A/S, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $73.00K | $- | $- | $- | $- |
| Cost of Revenue | $112 | $571.32K | $343.45K | $105.72K | $80.98K |
| Gross Profit | $72.89K | $-571.32K | $-343.45K | $-105.72K | $-80.98K |
| Gross Profit Ratio | 99.85% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $11.92M | $17.06M | $19.58M | $10.90M | $8.22M |
| General and Administrative Expenses | $10.35M | $8.21M | $6.25M | $5.67M | $2.63M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $10.35M | $8.21M | $6.25M | $5.67M | $2.63M |
| Other Expenses | $- | $- | $- | $- | $16.00K |
| Operating Expenses | $22.25M | $25.26M | $25.83M | $16.57M | $10.86M |
| Cost and Expenses | $22.27M | $25.26M | $25.83M | $16.57M | $10.86M |
| Interest Income | $154.00K | $2.83M | $2.04M | $216.00K | $9.00K |
| Interest Expense | $897.00K | $1.51M | $915.00K | $223.00K | $1.22M |
| Depreciation and Amortization | $615.95K | $571.32K | $343.45K | $105.72K | $80.98K |
| EBITDA | $-21.40M | $-22.58M | $-24.17M | $-16.46M | $-11.90M |
| EBITDA Ratio | -29319.18% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-22.20M | $-25.26M | $-25.83M | $-16.57M | $-10.86M |
| Operating Income Ratio | -30406.85% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $-718.00K | $1.32M | $1.12M | $-7.00K | $-1.16M |
| Income Before Tax | $-22.91M | $-23.94M | $-24.71M | $-16.57M | $-12.02M |
| Income Before Tax Ratio | -31390.41% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $-791.22K | $-772.00K | $-178.00K | $-1.56M | $-825.00K |
| Net Income | $-22.12M | $-23.17M | $-24.53M | $-15.02M | $-11.20M |
| Net Income Ratio | -30308.22% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-1.62 | $-1.96 | $-2.52 | $-1.85 | $-1.38 |
| EPS Diluted | $-1.62 | $-1.96 | $-2.52 | $-1.85 | $-1.38 |
| Weighted Average Shares Outstanding | 13.67M | 11.82M | 9.75M | 8.10M | 8.10M |
| Weighted Average Shares Outstanding Diluted | 13.67M | 11.82M | 9.75M | 8.10M | 8.10M |
| SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | November 14, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.03M | $153.89K | $50.88K | $73.60K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $3.03M | $153.89K | $50.88K | $73.60K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $2.62M | $2.75M | $2.83M | $2.32M | $2.83M | $2.94M | $3.85M | $4.07M | $4.07M | $4.11M | $4.80M | $6.15M | $4.42M | $5.11M | $3.89M | $2.85M | $2.97M | $2.57M | $2.51M | $2.95M |
| General and Administrative Expenses | $2.13M | $1.98M | $1.61M | $1.86M | $2.93M | $2.74M | $2.54M | $2.45M | $2.02M | $2.15M | $1.59M | $1.57M | $1.50M | $1.92M | $1.28M | $1.79M | $1.72M | $1.37M | $781.00K | $761.00K |
| Selling and Marketing Expenses | $- | $-1.45K | $-3.75K | $292.52K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $2.13M | $1.98M | $1.61M | $2.16M | $2.93M | $2.74M | $2.54M | $2.45M | $2.02M | $2.15M | $1.59M | $1.57M | $1.50M | $1.92M | $1.28M | $1.79M | $1.72M | $1.37M | $781.00K | $761.00K |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $71.00K | $- | $- | $- | $12.00K | $- | $- | $- | $16.00K |
| Operating Expenses | $4.76M | $4.73M | $4.44M | $4.47M | $5.76M | $5.68M | $6.39M | $6.53M | $6.08M | $6.26M | $6.40M | $7.72M | $5.91M | $7.03M | $5.17M | $4.64M | $4.68M | $3.94M | $3.29M | $3.72M |
| Cost and Expenses | $4.76M | $4.73M | $4.44M | $4.47M | $5.76M | $5.68M | $6.39M | $6.53M | $6.08M | $6.26M | $6.40M | $7.72M | $5.91M | $7.03M | $5.17M | $4.64M | $4.68M | $3.94M | $3.29M | $3.72M |
| Interest Income | $84.26K | $41.00K | $5.62M | $541.33K | $72.00K | $47.00K | $285.00K | $70.00K | $703.00K | $1.54M | $519.00K | $746.00K | $288.00K | $33.00K | $972.00K | $93.00K | $100.00K | $6.00K | $16.00K | $30.00K |
| Interest Expense | $385.21K | $225.00K | $246.00K | $111.00K | $182.00K | $278.00K | $326.00K | $590.00K | $535.00K | $225.00K | $158.00K | $72.00K | $51.00K | $495.00K | $297.00K | $214.00K | $3.00K | $- | $4.00K | $- |
| Depreciation and Amortization | $89.46K | $37.66K | $99.75K | $99.75K | $200.00K | $150.00K | $89.25K | $89.25K | $41.25K | $41.25K | $41.25K | $41.25K | $26.25K | $8.00K | $8.00K | $29.00K | $25.33K | $20.25K | $20.25K | $30.00K |
| EBITDA | $-1.65M | $-4.54M | $1.22M | $-4.26M | $-5.56M | $-5.63M | $-6.14M | $-6.51M | $-5.35M | $-4.69M | $-5.87M | $-7.68M | $-5.61M | $-6.98M | $-4.19M | $-4.62M | $-4.65M | $-3.92M | $-3.27M | $-3.69M |
| EBITDA Ratio | -54.42% | -2950.22% | 2401.68% | -6235.31% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-1.74M | $-4.58M | $-4.39M | $-4.40M | $-5.76M | $-5.68M | $-6.39M | $-6.53M | $-6.08M | $-6.26M | $-6.40M | $-7.72M | $-5.91M | $-7.03M | $-5.17M | $-4.64M | $-4.68M | $-3.94M | $-3.29M | $-3.72M |
| Operating Income Ratio | -57.37% | -2974.69% | -8619.64% | -5978.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $-300.95K | $-1.81M | $5.37M | $-338.75K | $-110.00K | $-231.00K | $-41.00K | $-520.00K | $168.00K | $1.31M | $361.00K | $674.00K | $237.00K | $-462.00K | $675.00K | $-126.32K | $97.00K | $6.00K | $12.00K | $-55.00K |
| Income Before Tax | $-2.04M | $-6.39M | $973.73K | $-4.74M | $-5.87M | $-5.91M | $-6.43M | $-7.04M | $-5.92M | $-4.95M | $-6.04M | $-7.05M | $-5.67M | $-7.49M | $-4.50M | $-4.77M | $-4.59M | $-3.94M | $-3.28M | $-3.78M |
| Income Before Tax Ratio | -67.32% | -4153.92% | 1913.73% | -6438.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $-96.30K | $-198.85K | $-217.49K | $-178.45K | $-194.00K | $-225.00K | $-194.00K | $-173.00K | $-175.00K | $-177.00K | $-247.00K | $1.32M | $-425.00K | $-669.00K | $-407.00K | $-502.00K | $-578.00K | $-296.00K | $-180.00K | $-259.00K |
| Net Income | $-1.94M | $-6.19M | $1.19M | $-4.56M | $-5.68M | $-5.68M | $-6.24M | $-6.87M | $-5.74M | $-4.77M | $-5.79M | $-8.37M | $-5.25M | $-6.82M | $-4.09M | $-4.26M | $-4.01M | $-3.64M | $-3.10M | $-3.52M |
| Net Income Ratio | -64.14% | -4024.70% | 2346.65% | -6195.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.07 | $-0.23 | $0.05 | $-0.33 | $-0.41 | $-0.42 | $-0.48 | $-0.57 | $-0.48 | $-0.41 | $-0.50 | $-0.77 | $-0.55 | $-0.72 | $-0.46 | $-0.53 | $-0.50 | $-0.38 | $-0.32 | $-0.37 |
| EPS Diluted | $-0.07 | $-0.23 | $0.05 | $-0.33 | $-0.41 | $-0.42 | $-0.48 | $-0.57 | $-0.48 | $-0.40 | $-0.50 | $-0.77 | $-0.55 | $-0.72 | $-0.46 | $-0.53 | $-0.50 | $-0.38 | $-0.32 | $-0.37 |
| Weighted Average Shares Outstanding | 27.63M | 27.06M | 23.32M | 13.67M | 13.83M | 13.53M | 12.89M | 12.07M | 11.92M | 11.60M | 11.58M | 10.84M | 9.60M | 9.47M | 8.90M | 8.10M | 8.10M | 9.60M | 9.60M | 9.60M |
| Weighted Average Shares Outstanding Diluted | 27.63M | 27.06M | 23.32M | 13.67M | 13.83M | 13.53M | 12.89M | 12.07M | 11.92M | 11.92M | 11.58M | 10.84M | 9.60M | 9.47M | 8.90M | 8.10M | 8.10M | 9.60M | 9.60M | 9.60M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $5.58M | $13.18M | $32.17M | $5.83M | $9.56M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $5.58M | $13.18M | $32.17M | $5.83M | $9.56M |
| Net Receivables | $1.07M | $- | $- | $- | $931.00K |
| Inventory | $- | $-2.49M | $-1.90M | $-6.91M | $-6 |
| Other Current Assets | $1.69M | $2.49M | $3.18M | $6.29M | $468.00K |
| Total Current Assets | $8.35M | $13.97M | $34.70M | $5.83M | $10.96M |
| Property Plant Equipment Net | $4.34M | $4.67M | $5.37M | $457.00K | $126.00K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $93.00K | $100.00K | $- |
| Goodwill and Intangible Assets | $- | $- | $93.00K | $100.00K | $- |
| Long Term Investments | $29.00K | $209.00K | $- | $5.31M | $- |
| Tax Assets | $- | $- | $- | $262.00K | $- |
| Other Non-Current Assets | $167.00K | $156.00K | $- | $2.00K | $- |
| Total Non-Current Assets | $4.54M | $5.04M | $5.46M | $6.13M | $126.00K |
| Other Assets | $- | $-77.95M | $- | $- | $- |
| Total Assets | $12.89M | $-58.94M | $40.16M | $11.96M | $11.08M |
| Account Payables | $2.69M | $2.08M | $2.85M | $3.67M | $646.00K |
| Short Term Debt | $485.00K | $439.00K | $440.00K | $40.00K | $36.00K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $3.91M | $1.24M | $1.03M | $1.21M | $1.04M |
| Total Current Liabilities | $7.08M | $3.76M | $4.32M | $4.93M | $1.72M |
| Long Term Debt | $10.38M | $3.90M | $3.25M | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $159.00K | $6.06M | $153.00K | $- | $- |
| Total Non-Current Liabilities | $10.54M | $9.96M | $3.40M | $- | $- |
| Other Liabilities | $-10.00K | $- | $- | $- | $- |
| Total Liabilities | $17.62M | $13.72M | $7.73M | $4.93M | $1.72M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $5.90M | $3.89M | $3.75M | $2.65M | $2.48M |
| Retained Earnings | $-107.97M | $-72.66M | $-50.43M | $-27.28M | $-15.81M |
| Accumulated Other Comprehensive Income Loss | $-3.77M | $-3.65M | $79.11M | $31.67M | $22.69M |
| Other Total Stockholders Equity | $101.11M | $80.73M | $-82.87M | $- | $- |
| Total Stockholders Equity | $-4.73M | $-72.66M | $-50.43M | $7.04M | $9.36M |
| Total Equity | $-4.73M | $-72.66M | $-50.43M | $7.04M | $9.36M |
| Total Liabilities and Stockholders Equity | $12.89M | $-58.94M | $-42.71M | $11.96M | $11.08M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $12.89M | $-58.94M | $-42.71M | $11.96M | $11.08M |
| Total Investments | $29.00K | $209.00K | $- | $5.31M | $- |
| Total Debt | $10.87M | $2.25M | $3.69M | $20.00K | $36.00K |
| Net Debt | $5.29M | $-10.93M | $-28.48M | $-5.81M | $-9.52M |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | November 14, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $4.58M | $7.99M | $11.73M | $5.58M | $2.60M | $7.12M | $10.24M | $13.18M | $17.85M | $25.25M | $31.41M | $32.17M | $11.94M | $18.80M | $26.95M | $5.83M | $7.88M | $-9.56M | $9.56M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $26.37K | $- | $50.50K | $- | $- | $- | $- | $- | $- | $- | $- | $19.12M | $- |
| Cash and Short Term Investments | $4.58M | $7.99M | $11.73M | $5.58M | $2.60M | $7.12M | $10.24M | $13.18M | $17.85M | $25.25M | $31.41M | $32.17M | $11.94M | $18.80M | $26.95M | $5.83M | $7.88M | $9.56M | $9.56M |
| Net Receivables | $- | $2.71M | $- | $- | $- | $4.25M | $- | $- | $- | $1.30M | $1.38M | $1.90M | $- | $- | $1.61M | $- | $475.00K | $- | $931.00K |
| Inventory | $- | $- | $- | $- | $- | $-4.25K | $- | $-2.49M | $- | $- | $- | $- | $- | $- | $3.90M | $-5.12M | $- | $- | $- |
| Other Current Assets | $-4.58M | $- | $- | $1.69M | $4.25M | $- | $- | $2.49M | $- | $1.98M | $2.59M | $638.00K | $2.65M | $2.83M | $3.92M | $2.90M | $2.06M | $- | $468.00K |
| Total Current Assets | $- | $10.70M | $11.73M | $8.35M | $2.60M | $11.37M | $10.24M | $13.97M | $17.85M | $28.53M | $35.38M | $34.70M | $16.32M | $23.43M | $32.49M | $5.83M | $10.41M | $9.56M | $10.96M |
| Property Plant Equipment Net | $- | $3.90M | $- | $4.34M | $4.31M | $4.58M | $- | $4.67M | $- | $4.87M | $5.28M | $5.37M | $5.35M | $2.28M | $1.79M | $457.00K | $213.00K | $- | $126.00K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $84.92K | $- | $- | $- | $- | $-1 | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $85 | $91.00K | $93.00K | $95.00K | $97.00K | $96.00K | $100.00K | $37.00K | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $85.00K | $91.00K | $93.00K | $95.00K | $97.00K | $96.00K | $100.00K | $37.00K | $- | $- |
| Long Term Investments | $- | $463.01K | $- | $29.00K | $- | $638.99K | $- | $209.00K | $- | $- | $- | $- | $- | $- | $232.00K | $5.31M | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $133.00K | $252.00K | $179.00K | $262.00K | $- | $- | $- |
| Other Non-Current Assets | $- | $165.01K | $10.92M | $167.00K | $7.63M | $165.01K | $10.25M | $156.00K | $9.59M | $518.00K | $334.00K | $- | $2.22M | $1.61M | $133.00K | $2.00K | $612.00K | $-9.56M | $- |
| Total Non-Current Assets | $- | $4.53M | $10.92M | $4.54M | $11.94M | $5.39M | $10.25M | $5.04M | $9.59M | $5.47M | $5.70M | $5.46M | $7.80M | $4.23M | $2.43M | $6.13M | $862.00K | $-9.56M | $126.00K |
| Other Assets | $15.19M | $-147 | $- | $- | $-89.63M | $- | $-85.30M | $-77.95M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $15.19M | $15.23M | $22.65M | $12.89M | $-75.09M | $16.75M | $-64.81M | $-58.94M | $27.45M | $34.00M | $41.08M | $40.16M | $24.12M | $27.66M | $34.92M | $11.96M | $11.28M | $- | $11.08M |
| Account Payables | $- | $2.56M | $- | $2.69M | $2.61M | $1.69M | $- | $2.08M | $- | $2.44M | $2.49M | $2.85M | $538.00K | $1.55M | $3.41M | $3.67M | $1.50M | $- | $646.00K |
| Short Term Debt | $- | $477.00K | $- | $485.00K | $150.00K | $470.00K | $- | $439.00K | $- | $411.00K | $436.00K | $440.00K | $478.00K | $136.00K | $55.00K | $40.00K | $38.00K | $- | $36.00K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $2 | $- | $1.49M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $- | $786.12K | $- | $3.91M | $-2.76M | $1.90M | $- | $1.24M | $- | $1.56M | $1.76M | $1.03M | $2.91M | $3.11M | $2.55M | $1.21M | $1.83M | $- | $1.04M |
| Total Current Liabilities | $- | $3.82M | $- | $7.08M | $4.69M | $4.05M | $- | $3.76M | $- | $4.41M | $4.69M | $4.32M | $3.92M | $4.80M | $6.02M | $4.93M | $3.37M | $- | $1.72M |
| Long Term Debt | $- | $10.01M | $- | $10.38M | $- | $10.02M | $- | $3.90M | $- | $9.30M | $9.86M | $3.25M | $3.39M | $974.00K | $1.05M | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $145.33K | $- | $148.69K | $- | $147.00K | $- | $6.06M | $- | $141.00K | $150.00K | $153.00K | $157.00K | $53.00K | $52.00K | $- | $- | $- | $- |
| Total Non-Current Liabilities | $- | $10.16M | $20.05M | $10.53M | $14.68M | $10.17M | $13.91M | $9.96M | $13.90M | $9.45M | $10.01M | $3.40M | $3.54M | $1.03M | $1.10M | $2.67M | $1.54M | $- | $682.00K |
| Other Liabilities | $15.19M | $- | $20.05M | $- | $-4.69M | $- | $- | $- | $13.90M | $- | $- | $- | $- | $- | $- | $-2.67M | $-1.54M | $- | $-682.00K |
| Total Liabilities | $15.19M | $13.98M | $20.05M | $17.62M | $14.68M | $14.22M | $13.91M | $13.72M | $13.90M | $13.85M | $14.69M | $7.73M | $7.47M | $5.83M | $7.12M | $4.93M | $3.37M | $- | $1.72M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $- | $8.24M | $7.96M | $5.90M | $4.41M | $4.39M | $4.22M | $3.89M | $3.86M | $3.84M | $3.75M | $3.75M | $3.13M | $3.13M | $3.13M | $2.65M | $2.60M | $- | $2.48M |
| Retained Earnings | $-114.90M | $-112.97M | $-112.03M | $-107.97M | $-89.76M | $-84.26M | $-78.72M | $-72.66M | $-65.76M | $-60.33M | $-55.88M | $-50.43M | $-42.14M | $-37.47M | $-31.08M | $-27.28M | $-23.77M | $- | $-15.81M |
| Accumulated Other Comprehensive Income Loss | $- | $105.98M | $106.67M | $9.89M | $82.61M | $82.40M | $81.08M | $-3.65M | $75.44M | $76.63M | $78.51M | $79.11M | $55.66M | $56.17M | $55.74M | $31.67M | $29.07M | $9.36M | $22.69M |
| Other Total Stockholders Equity | $114.98M | $- | $-1 | $101.11M | $-4.42M | $- | $-8.30M | $80.73M | $-79.31M | $- | $- | $-82.87M | $- | $- | $- | $- | $- | $- | $- |
| Total Stockholders Equity | $74.00K | $1.25M | $2.60M | $-4.73M | $-89.76M | $2.54M | $-78.72M | $-72.66M | $-65.76M | $20.15M | $26.39M | $-50.43M | $16.65M | $21.83M | $27.80M | $7.04M | $7.90M | $9.36M | $9.36M |
| Total Equity | $74.00K | $1.25M | $2.60M | $-4.73M | $-89.76M | $2.54M | $-78.72M | $-72.66M | $-65.76M | $20.15M | $26.39M | $-50.43M | $16.65M | $21.83M | $27.80M | $7.04M | $7.90M | $9.36M | $9.36M |
| Total Liabilities and Stockholders Equity | $15.26M | $15.23M | $22.65M | $12.89M | $-75.09M | $16.75M | $-64.81M | $-58.94M | $27.45M | $34.00M | $41.08M | $-42.71M | $24.12M | $27.66M | $34.92M | $11.96M | $11.28M | $9.36M | $11.08M |
| Minority Interest | $- | $- | $-2.93K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $15.26M | $15.23M | $22.65M | $12.89M | $-75.09M | $16.75M | $-64.81M | $-58.94M | $27.45M | $34.00M | $41.08M | $-42.71M | $24.12M | $27.66M | $34.92M | $11.96M | $11.28M | $9.36M | $11.08M |
| Total Investments | $- | $463.01K | $- | $29.00K | $- | $638.99K | $26.37K | $209.00K | $50.50K | $- | $- | $- | $- | $- | $232.00K | $5.31M | $- | $19.12M | $- |
| Total Debt | $- | $10.49M | $- | $10.87M | $9.99M | $10.49M | $- | $2.25M | $- | $9.72M | $10.29M | $3.69M | $3.87M | $1.11M | $1.11M | $20.00K | $38.00K | $- | $36.00K |
| Net Debt | $-4.58M | $2.50M | $-11.73M | $5.29M | $7.39M | $3.37M | $-10.24M | $-10.93M | $-17.85M | $-15.54M | $-21.12M | $-28.48M | $-8.08M | $-17.69M | $-25.85M | $-5.81M | $-7.84M | $9.56M | $-9.52M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-22.12M | $-23.17M | $-24.53M | $-15.02M | $-11.20M |
| Depreciation and Amortization | $615.00K | $571.00K | $344.00K | $105.00K | $81.00K |
| Deferred Income Tax | $-984.00K | $-998.00K | $-190.00K | $-2.07M | $-825.00K |
| Stock Based Compensation | $479.00K | $942.00K | $1.38M | $3.41M | $2.36M |
| Change in Working Capital | $1.56M | $-2.88M | $1.24M | $215.00K | $566.00K |
| Accounts Receivables | $1.11M | $-1.49M | $1.86M | $-2.52M | $-337.00K |
| Inventory | $- | $1.49M | $-1.86M | $2.52M | $403.00K |
| Accounts Payables | $502.00K | $-599.00K | $-647.00K | $1.80M | $507.00K |
| Other Working Capital | $-48.70K | $-2.28M | $1.88M | $-1.58M | $-7.00K |
| Other Non Cash Items | $2.76M | $-243.00K | $-171.00K | $919.00K | $1.99M |
| Net Cash Provided by Operating Activities | $-17.69M | $-25.77M | $-21.93M | $-12.44M | $-7.03M |
| Investments in Property Plant and Equipment | $-87.13K | $-292.00K | $-1.36M | $-393.00K | $-61.00K |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $-6.00K | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $24.01K | $29.95K | $- | $- |
| Other Investing Activities | $133 | $-13 | $48 | $-244.00K | $-7.00K |
| Net Cash Used for Investing Activities | $-93.00K | $-268.00K | $-1.33M | $-393.00K | $-61.00K |
| Debt Repayment | $-632.00K | $7.42M | $-289.00K | $- | $79.00K |
| Common Stock Issued | $9.17M | $428.00K | $53.85M | $9.02M | $9.44M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $2.15M | $- | $-3.76M | $-202.00K | $-13.00K |
| Net Cash Used Provided by Financing Activities | $10.69M | $7.85M | $49.80M | $8.82M | $9.51M |
| Effect of Forex Changes on Cash | $-508.00K | $-793.00K | $-210.00K | $288.00K | $-295.00K |
| Net Change in Cash | $-7.60M | $-18.98M | $26.33M | $-3.73M | $2.13M |
| Cash at End of Period | $5.58M | $13.18M | $32.17M | $5.83M | $9.56M |
| Cash at Beginning of Period | $13.18M | $32.17M | $5.83M | $9.56M | $7.43M |
| Operating Cash Flow | $-17.69M | $-25.77M | $-21.93M | $-12.44M | $-7.03M |
| Capital Expenditure | $-87.00K | $-292.00K | $-1.36M | $-393.00K | $-61.00K |
| Free Cash Flow | $-17.78M | $-26.07M | $-23.29M | $-12.83M | $-7.09M |
Cash Flow Charts
| Breakdown | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | November 14, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $1.19M | $-4.52M | $-5.68M | $-5.68M | $-6.24M | $-6.87M | $-5.74M | $-4.77M | $-5.79M | $-8.37M | $-5.25M | $-6.82M | $-4.09M | $-4.26M | $-4.01M | $-3.64M | $-3.10M | $-3.52M |
| Depreciation and Amortization | $- | $115.00K | $200.00K | $- | $- | $571.00K | $- | $- | $- | $344.00K | $- | $- | $- | $29.00K | $- | $- | $- | $30.00K |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.01M | $- | $- | $- | $-259.00K |
| Stock Based Compensation | $- | $-21.00K | $100.00K | $- | $- | $-58.00K | $300.00K | $- | $- | $79.00K | $600.00K | $400.00K | $- | $625.00K | $1.60M | $500.00K | $- | $637.00K |
| Change in Working Capital | $- | $904.00K | $707.00K | $- | $- | $465.00K | $-801.00K | $427.00K | $-2.17M | $1.84M | $-906.00K | $-738.00K | $1.04M | $131.00K | $166.00K | $297.00K | $-358.00K | $14.00K |
| Accounts Receivables | $- | $707.00K | $800.00K | $- | $- | $-1.49M | $1.10M | $-1.10K | $- | $1.86M | $- | $- | $- | $-2.50M | $- | $- | $- | $-337.00K |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $- | $197.00K | $-93.00K | $- | $- | $1.95M | $-1.90M | $428.10K | $-2.17M | $1.84M | $-906.00K | $-738.00K | $1.04M | $813.00K | $166.00K | $297.00K | $-358.00K | $14.00K |
| Other Non Cash Items | $-1.19M | $1.52M | $281.00K | $5.68M | $6.24M | $63.00K | $-326.00K | $-849.00K | $-226.00K | $2.41M | $-139.00K | $69.00K | $-980.00K | $98.00K | $1.08M | $1.04M | $507.00K | $883.00K |
| Net Cash Provided by Operating Activities | $- | $-2.01M | $-4.39M | $- | $- | $-5.83M | $-6.57M | $-5.19M | $-8.19M | $-4.12M | $-6.29M | $-7.49M | $-4.04M | $-4.39M | $-2.77M | $-2.30M | $-2.95M | $-2.21M |
| Investments in Property Plant and Equipment | $- | $1.00K | $-65.00K | $- | $- | $61.00K | $-89.00K | $-83.00K | $-181.00K | $-176.00K | $-332.00K | $-510.00K | $-342.00K | $-281.00K | $-2.00K | $-45.00K | $-64.00K | $-47.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $21.95K | $-932 | $30.88K | $-14.96K | $14.96K | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $-5.00K | $1.00K | $6.00K | $22.00K | $-1.00K | $1.00K | $15.00K | $-45.00K | $-189.00K | $-3.00K | $-35.00K | $-17.00K | $-7.00K |
| Net Cash Used for Investing Activities | $- | $1.00K | $-65.00K | $- | $- | $56.00K | $-88.00K | $-77.00K | $-159.00K | $-177.00K | $-331.00K | $-495.00K | $-327.00K | $-281.00K | $-5.00K | $-45.00K | $-81.00K | $-47.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $-107.00K | $7.74M | $-144.00K | $-67.00K | $-35.00K | $-43.00K | $-20.00K | $-19.00K | $-18.00K | $-18.00K | $-18.00K |
| Common Stock Issued | $- | $- | $- | $- | $- | $-25.98M | $- | $28.00K | $- | $25.95M | $1.00K | $14.94K | $27.90M | $2.39M | $6.63M | $- | $- | $262.00K |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $5.26M | $96.00K | $- | $- | $546.00K | $-131.00K | $-221.00K | $- | $-1.16M | $1.00K | $- | $-2.60M | $- | $-128.00K | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $- | $5.26M | $96.00K | $- | $- | $546.00K | $-131.00K | $-300.00K | $7.74M | $24.65M | $-65.00K | $-35.00K | $25.25M | $2.37M | $6.48M | $-18.00K | $-18.00K | $244.00K |
| Effect of Forex Changes on Cash | $- | $-274.00K | $-154.00K | $- | $- | $560.00K | $-613.00K | $-590.00K | $-150.00K | $-139.00K | $-164.00K | $-138.00K | $231.00K | $258.00K | $81.00K | $106.00K | $-165.00K | $105.00K |
| Net Change in Cash | $- | $2.98M | $-4.51M | $-3.12M | $-2.94M | $-4.67M | $-7.40M | $-6.16M | $-757.00K | $20.22M | $-6.86M | $-8.16M | $21.12M | $-2.04M | $3.79M | $-2.26M | $-3.21M | $-1.91M |
| Cash at End of Period | $5.58M | $5.58M | $2.60M | $7.12M | $10.24M | $13.18M | $17.85M | $25.25M | $31.41M | $32.17M | $11.94M | $18.80M | $26.95M | $5.83M | $7.88M | $4.08M | $6.34M | $9.56M |
| Cash at Beginning of Period | $5.58M | $2.60M | $7.12M | $10.24M | $13.18M | $17.85M | $25.25M | $31.41M | $32.17M | $11.94M | $18.80M | $26.95M | $5.83M | $7.88M | $4.08M | $6.34M | $9.56M | $11.47M |
| Operating Cash Flow | $- | $-2.01M | $-4.39M | $- | $- | $-5.83M | $-6.57M | $-5.19M | $-8.19M | $-4.12M | $-6.29M | $-7.49M | $-4.04M | $-4.39M | $-2.77M | $-2.30M | $-2.95M | $-2.21M |
| Capital Expenditure | $- | $1.00K | $-65.00K | $- | $- | $61.00K | $-89.00K | $-83.00K | $-181.00K | $-176.00K | $-332.00K | $-510.00K | $-342.00K | $-281.00K | $-2.00K | $-45.00K | $-64.00K | $-47.00K |
| Free Cash Flow | $- | $-2.01M | $-4.46M | $- | $- | $-5.77M | $-6.66M | $-5.27M | $-8.37M | $-4.29M | $-6.63M | $-8.00M | $-4.38M | $-4.67M | $-2.77M | $-2.35M | $-3.01M | $-2.26M |
Evaxion Biotech A/S Stock Forecast
Analyst ratings, price targets, and earnings estimates for EVAX.
EVAX Analyst Ratings
Strong Buy
Based on 2 analysts in the past 3 months
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
| Date | Analyst | Firm | Price Target | Price When Posted | Upside |
|---|
Evaxion Biotech A/S Dividends
Explore Evaxion Biotech A/S's dividend history, including dividend yield, payout ratio, and historical payments.
Peers: Biotechnology
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
| Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|
Sigilon Therapeutics, Inc.
SGTX
|
$56.22M | $22.47 | $-1.34 | $-3.39 | $3.77 |
Reviva Pharmaceuticals Holdings, Inc.
RVPH
|
$83.84M | $1.80 | $-1649739.56 | $0.00 | $21.43 |
ZyVersa Therapeutics, Inc.
ZVSA
|
$3.11M | $1.24 | $-1008.15 | $-0.01 | $0.08 |
Kiromic BioPharma, Inc.
KRBP
|
$2.27M | $1.48 | $-1.03 | $-0.87 | $-1.86 |
Unicycive Therapeutics, Inc.
UNCY
|
$61.46M | $0.59 | $-1.24 | $-0.70 | $-5.59 |
Quoin Pharmaceuticals, Ltd.
QNRX
|
$1.67M | $0.31 | $-9.64 | $-0.51 | $0.78 |
Allarity Therapeutics, Inc.
ALLR
|
$4.34M | $0.98 | $-0.01 | $-55311.38 | $-239280.53 |
Virax Biolabs Group Limited
VRAX
|
$8.27M | $1.90 | $-3.36 | $-0.22 | $0.27 |
Biodexa Pharmaceuticals Plc
BDRX
|
$6.20K | $4.27 | $-224.13 | $0.00 | $0.00 |
Lyell Immunopharma, Inc.
LYEL
|
$178.25M | $0.61 | $-0.93 | $-2.08 | $0.74 |
Cullinan Oncology, Inc.
CGEM
|
$554.91M | $9.53 | $-3.69 | $-2.76 | $0.93 |
Monte Rosa Therapeutics, Inc.
GLUE
|
$416.54M | $6.78 | $-2.63 | $-2.15 | $1.62 |
Theseus Pharmaceuticals, Inc.
THRX
|
$181.50M | $4.07 | $-1.22 | $-4.07 | $0.92 |
Revolution Medicines, Inc.
RVMD
|
$7.42B | $40.67 | $-3.86 | $-7.44 | $1.78 |
eFFECTOR Therapeutics, Inc.
EFTR
|
$941 | $0.00 | $-16.37 | $-0.71 | $-4.41 |
Landos Biopharma, Inc.
LABP
|
$71.68M | $22.93 | $-3.50 | $-1.05 | $0.72 |
Apexigen, Inc.
APGN
|
$9.57M | $0.39 | $-1.59 | $-0.43 | $2.12 |
Navidea Biopharmaceuticals, Inc.
NAVB
|
$70.06K | $0.00 | $-0.52 | $-0.41 | $-0.73 |
Angion Biomedica Corp.
ANGN
|
$30.11M | $1.00 | $0.00 | $0.00 | $0.00 |
Revelation Biosciences, Inc.
REVB
|
$2.24M | $4.28 | $-0.53 | $-455.68 | $8.24 |
Zura Bio Limited
ZURA
|
$101.20M | $1.55 | $-1.83 | $-2.38 | $2.42 |
Phio Pharmaceuticals Corp.
PHIO
|
$8.65M | $1.81 | $-46.87 | $-0.15 | $0.20 |
TransCode Therapeutics, Inc.
RNAZ
|
$7.21M | $10.36 | $-103.61 | $-2.10 | $23.72 |
Related Metrics
Explore detailed financial metrics and analysis for EVAX.